MDCXW

distress 10/10 · high distress / dilution risk

$0.46+18%today-82% from 52w high

medicuspharma.com16 employeesFounded 2008West Conshohocken, PA

Revenue

pre-revenue

Liquidity

$6M

Runway

0.2 yrs

Shares 1y

+218%

Price & events

-81.6% over 6M

CatalystRating changeDilutionFinancingdashed = today

+17.9%

-11.5%

-32.3%

-81.6%

—

-81.6%

All

Overview

Market Cap: $26.06M
Volume: 224
52 Week Range: $0.39 – $2.50
Total Shares: 56.66M
Float Shares: 50.34M
RVOL: 0.26x
Beta: -0.65

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 2

2025-08-04partnershipEntered non-binding MoU with HelixNano to form JV for co-development of thermostable mRNA vaccines using MNA delivery platform.SEC 8-K
2025-06-29partnershipTeverelix · Entry into definitive securities exchange agreement to acquire Antev Limited.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 56,658,164 · 59 offerings/1y · 5 PIPEs

2026-06-04424B3offering
2026-05-28424B3offering
2026-05-278-Kmaterial_agreement
2026-05-14424B3offering
2026-04-30424B3offering
2026-04-27424B3offering
2026-04-248-Kmaterial_agreement

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors

none identified